Chest
Clinical InvestigationsSARCOIDOSISStudy of Clara Cell 16, KL-6, and Surfactant Protein-D in Serum as Disease Markers in Pulmonary Sarcoidosis
Section snippets
Study Subjects
In this study, patients with sarcoidosis diagnosed at the Department of Pulmonology of the St. Antonius Hospital Nieuwegein between 1989 and 1999 were studied retrospectively. In all patients, the diagnosis of sarcoidosis was based on compatible clinical findings, histologic evidence of noncaseating epithelioid-cell granulomas, and the exclusion of known causes of granulomatous diseases. At time of presentation, none of them were receiving corticosteroids, nor had they within the previous 3
Clinical Characteristics
Seventy-nine patients with sarcoidosis (43 men and 36 women; mean age ± SD, 39 ± 12 years; 56 nonsmokers and 23 smokers), and 38 control subjects (19 men and 19 women; mean age, 37 ± 10 years; all nonsmokers) were studied.
One patient with sarcoidosis presented with radiographic stage 0, 28 patients presented with stage I, 36 patients presented with stage II, 12 patients presented with stage III, and 2 patients presented with stage IV disease. Serum CC16, KL-6, and SP-D values in patients with
Discussion
In this study, we compared the value of CC16, KL-6, and SP-D as serum markers in pulmonary sarcoidosis. Although all three pneumoproteins were significantly elevated in patients with sarcoidosis compared to control subjects, ROC curve analysis revealed best sensitivity for KL-6. The results on KL-6 are in agreement with a recent study of Ohnishi and colleagues,10 who demonstrated superiority of serum KL-6 over SP-D in detecting interstitial lung disease. However, their study did not include
ACKNOWLEDGMENT
The authors thank Xavier Dumont for laboratory assistance and Pieter Zanen for statistical advice.
References (20)
- et al.
Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis
Chest
(1996) - et al.
The molecular mass and concentrations of protein 1 or Clara cell protein in biological fluids: a reappraisal
Clin Chim Acta
(1993) - et al.
Enzyme-linked immunosorbent assay using F(ab')2 fragment for the detection of human pulmonary surfactant protein D in sera
Clin Chim Acta
(1997) - et al.
Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers
Chest
(1996) - et al.
Serum Clara cell protein: an indicator of bronchial cell dysfunction caused by tobacco smoking
Environ Res
(1994) Statement on sarcoidosis: joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999
Am J Respir Crit Care Med
(1999)Sarcoidosis: clinical update
Eur Respir J Suppl
(2001)- et al.
Lung epithelium-specific proteins: characteristics and potential applications as markers
Am J Respir Crit Care Med
(1999) - et al.
Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids
Am J Respir Crit Care Med
(1995) - et al.
Serum Clara cell protein (CC16), a marker of the integrity of the air-blood barrier in sarcoidosis
Eur Respir J
(2001)
Cited by (69)
Krebs von den Lungen-6 (KL-6), soluble programmed cell death-1 (sPD-1) and its ligand-1(sPDL-1) in systemic sclerosis patients: Relation to disease parameters
2022, Egyptian RheumatologistCitation Excerpt :KL-6 antigen is expressed mainly by alveolar type II pneumocytes and respiratory bronchiolar epithelial cells and may act as a specific biomarker for predicting and monitoring ILD course [6]. Elevated serum levels of KL-6 have been associated with several respiratory conditions such as idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, SSc-ILD, myositis-associated ILD, sarcoidosis and advanced pulmonary tuberculosis [8,9]. Programmed cell death −1 (PD-1) protein, a member of the CD28 family of co-stimulatory molecules, delivers its pivotal inhibitory signals through interactions with its two major ligands, programmed death ligand-1 and −2 (PDL1 and 2).
Plasma matrix metalloproteinase 7, CC-chemokine ligand 18, and periostin as markers for pulmonary sarcoidosis
2020, Respiratory InvestigationDiagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype
2020, ChestCitation Excerpt :There is also evidence that specific HLA alleles, including HLA-DRB1∗1502, are associated with an increased risk of ILD in patients with RA.38,39 Elevations in levels of MMP-1 (serum), MMP-7 (serum, BALF, and induced sputum), and other MMPs are recognized in IPF (Table 2).13,43-78 In addition, serum and sputum from patients with IPF display significantly higher levels of IGFBP-2 (P < .001) compared with those from healthy subjects.46,47
Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?
2020, Seminars in Arthritis and RheumatismCitation Excerpt :In one study, SP-D distinguished IPF from other ILDs with sensitivity, specificity and accuracy of 70%, 65% and 68.5%, respectively [62]. However, in most studies, SP-D and SP-A were elevated in ILD (including lung cancers or infections) without specificity for one disease [68–71], suggesting that these biomarkers are rather general markers for alveolar damage than for specific diseases. Increased serum SP-A and SP-D were strong predictors of mortality in IPF in three independent studies [63–65], with better performance of a model combining both [65].
Walking the path of treatable traits in interstitial lung diseases
2023, Respiratory Research
Dr. Janssen was supported by a grant from AstraZeneca.